The UNLV department of brain health has formally launched the Chambers-Grundy Center for Transformative Neuroscience, offering hope through scientific discovery for patients who are suffering from Alzheimer’s, dementia and other brain and neurological diseases.

An experimental drug could help caregivers as well as patients, as it substantially improved agitation in Alzheimer's patients in a late-stage clinical trial. The announcement boosted the shares of the maker of the treatment, Axsome Therapeutics (AXSM), nearly 25% to more than $95.

Biogen Inc. stunned Alzheimer’s researchers in March when it said its highly awaited Alzheimer’s treatment aducanumab was unlikely to work. Seven months later, the company reversed course and said the drug did work after all -- at least in one of two large trials.

Nearly fifty-thousand Nevadans are currently living with Alzheimer's, and that number is only expected to skyrocket over the next decade. On this Nevada Week, we'll explore how close local researchers are to a cure. Plus, what role do citizen scientists and caregivers play toward fighting this neurodegenerative disease?

China has approved its first homegrown Alzheimer’s treatment — a novel drug based on algae, and the first breakthrough since 2003 in a field that has frustrated scientists and drug companies for decades.

Shanghai Green Valley Pharmaceuticals (Green Valley) announced today that China's National Medical Products Administration ( ANPM ) has approved oligo manato (GV-971) as a new drug for treatment of "Alzheimer's disease (AD) from benign to moderate and to improve cognitive function".

Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China's National Medical Products Administration (NMPA) has approved Oligomannate (GV-971) as new drug for the treatment of "mild to moderate Alzheimer's disease (AD) and improving cognitive function."

An expert panel reviews the causes of Alzheimer disease, as well as strategies used to detect mild cases and cognitive impairment.